TIGIT and melanoma: While the degree of TIGIT positivity was significantly higher in melanoma, head and neck, and cervical cancer compared to RCC, there was no significant difference in TIGIT+ T cell infiltration between RCC and NSCLC, a tumor type where anti-TIGIT therapies are being extensively studied with numerous late-stage clinical trials underway [21].